| Name | Title | Contact Details |
|---|
Constab Pharmaceuticals is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
Amring promotes health across communities by providing reliable, safe, and affordable medications bringing value to patients and improving quality of life.
Sandoz, a Division of the Novartis group, is a global leader in the field of generic pharmaceuticals, offering a wide array of high-quality, affordable products that are no longer protected by patents.
Canadian Pharmacists Association is a Ottawa, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.